← Back to patent-cliff list
SRD-4610
Tier C — Watch / tradeSRD-4610
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CCR4
Indications (approved)：Amyotrophic lateral sclerosis
Regional status
US
-
EU
-
China
Phase III
2024-12-31
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of SRD-4610?
Approved indications include: Amyotrophic lateral sclerosis.
When does the SRD-4610 patent expire?
No public expiry year is available for SRD-4610 yet; this page updates once verified.
How do I get a quote for SRD-4610 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01